Booster dose after 10 years is recommended following 17DD-YF primary vaccination

• Autor(a) principal: Azevedo, Ana Carolina Campi
• Data de Publicação: 2016
• Outros Autores: Pereira, Christian Costa, Antonelli, Lis Ribeiro do Valle, Fonseca, Cristina T, Carvalho, Andréa Teixeira, Rezende, Gabriela Villela, Santos, Raiany A, Batista, Maurício A, Campos, Fernanda M, Porto, Luiza Pacheco, Melo Júnior, Otoni A, Hossell, Débora MSH, Reis, Jordana G. Coelho dos, Magalhães, Vanessa Peruhype, Silva, Matheus F. Costa, Oliveira, Jaquelline G. de, Farias, Roberto H, Noronha, Tatiana G, Lemos, Jandira A, Von Doellinger, Vanessa dos R, Simões, Marisol, Souza, Mirian M de, Malaquias, Luiz C, Persi, Harold R, Pereira, Jorge M, Martins, José A, Ribeiro, Marcos Dornelas, Vinhas, Aline de A, Alves, Tatiane R, Maia, Maria de L, Freire, Marcos da S, Martins, Reinaldo de M, Homma, Akira, Romano, Alessandro PM, Domingues, Carla M, Tauil, Pedro L, Vasconcelos, Pedro Fernando da Costa, Rios, Maria, Caldas, Iramaya R, Camacho, Luiz A, Martins Filho, Olindo Assis
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Digital do Instituto Evandro Chagas (Patuá)
• Texto Completo: https://patua.iec.gov.br/handle/iec/2437
• topic: Imunidade / imunologia; Imunização Secundária; Febre Amarela / imunologia; Febre Amarela / prevenção & controle; Vacina contra Febre Amarela / administração & dosagem; Vacina contra Febre Amarela / imunologia; Fatores de Tempo; Citometria de Fluxo / métodos

A single vaccination of Yellow Fever vaccines is believed to confer life-long protection. In this study, results of vaccinees who received a single dose of 17DD-YF immunization followed over 10 y challenge this premise. YF-neutralizing antibodies, subsets of memory T and B cells as well as cytokine-producing lymphocytes were evaluated in groups of adults before (NVday0) and after (PVday30-45, PVyear1-4, PVyear5-9, PVyear10-11, PVyear12-13) 17DD-YF primary vaccination. YF-neutralizing antibodies decrease significantly from PVyear1-4 to PVyear12-13 as compared to PVday30-45, and the seropositivity rates (PRNT≥2.9Log10mIU/mL) become critical (lower than 90%) beyond PVyear5-9. YF-specific memory phenotypes (effector T-cells and classical B-cells) significantly increase at PVday30-45 as compared to na've baseline. Moreover, these phenotypes tend to decrease at PVyear10-11 as compared to PVday30-45. Decreasing levels of TNF-α(+) and IFN-γ(+) produced by CD4(+) and CD8(+) T-cells along with increasing levels of IL-10(+)CD4(+)T-cells were characteristic of anti-YF response over time. Systems biology profiling represented by hierarchic networks revealed that while the na've baseline is characterized by independent micro-nets, primary vaccinees displayed an imbricate network with essential role of central and effector CD8(+) memory T-cell responses. Any putative limitations of this cross-sectional study will certainly be answered by the ongoing longitudinal population-based investigation. Overall, our data support the current Brazilian national immunization policy guidelines that recommend one booster dose 10 y after primary 17DD-YF vaccination.